A causal link between autoantibodies and neurological symptoms in long COVID

Cell. 2026 May 28;189(11):3214-3235.e37. doi: 10.1016/j.cell.2026.04.042.

Abstract

Acute SARS-CoV-2 infection triggers the de novo production of diverse, functional autoantibodies (AABs) that remain elevated in long COVID (LC), but their pathogenic role remains unclear. Using tissue-based immunofluorescence, ELISA, human protein array, and mass spectrometry assays, we identified a broad range of AAB targets among individuals with LC. Individuals with neurocognitive symptoms showed increased AABs against central nervous system (CNS) and peripheral nervous system proteins. Purified immunoglobulin G (IgG) reacted with human locus coeruleus, thalamus, adrenal gland, and thyroid and cross-reacted with mouse sciatic nerve and meninges. CNS-reactive AABs correlated with several neurological symptoms. MED20-targeting IgG from patients with LC showed enhanced antibody-dependent phagocytosis. Passive transfer of IgG from individuals with LC into mice induced fatigue-like behavior, loss of balance/coordination, thermal hyperalgesia, small fiber nerve damage, and increased pain-related neuronal activity, recapitulating patients' symptoms. These findings suggest that targeting AABs might offer therapeutic benefits for this LC subgroup.

Keywords: SARS-CoV-2; autoantibodies; behavior; chronic pain; infectious diseases; long COVID; nociceptor; post-acute infection syndrome.

MeSH terms

  • Animals
  • Autoantibodies* / immunology
  • COVID-19* / complications
  • COVID-19* / immunology
  • Female
  • Humans
  • Immunoglobulin G / immunology
  • Male
  • Mice
  • Middle Aged
  • Nervous System Diseases* / immunology
  • Post-Acute COVID-19 Syndrome
  • Post-Infectious Disorders
  • SARS-CoV-2

Substances

  • Autoantibodies
  • Immunoglobulin G